Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 2/2010

01-02-2010 | Review Article

Biodegradable Intraocular Therapies for Retinal Disorders

Progress to Date

Authors: Noriyuki Kuno, PhD, Shinobu Fujii

Published in: Drugs & Aging | Issue 2/2010

Login to get access

Abstract

In general, it is difficult to achieve effective levels of drugs in the vitreous and the retina via topical and/or systemic administration. Intraocular drug delivery systems that achieve longer duration of pharmacological effect with lower administration frequency are urgently needed. Intraocular sustained drug release via implantable devices or injectable particles has been investigated for the treatment of various vitreoretinal disorders. Several non-biodegradable implants are available in clinical practice or in the late developmental phase: Vitrasert® (ganciclovir intravitreal implant) for cytomegalovirus retinitis, Retisert™ (fluocinolone acetonide intravitreal implant) for non-infectious uveitis, Iluvien™ (fluocinolone acetonide intravitreal implant) for diabetic macular oedema, and NT-501 (a polymer implant containing human retinal epithelial cells genetically modified to secrete ciliary neurotrophic factor) for non-neovascular (dry) age-related macular degeneration and/or retinitis pigmentosa. Many biodegradable formulations, including different shapes of rods, nail-like plugs, discs, or micro- or nano-particles, have also been investigated, but are not available as yet for the treatment of vitreoretinal disorders. The most developed biodegradable device, Ozurdex™ (dexamethasone intravitreal implant), is approved as first-line therapy for the treatment of macular oedema following branch retinal vein occlusion or central retinal vein occlusion.
In this article, we review the progress of major biodegradable drug delivery systems currently in clinical trials or in experimental stages for the treatment of vitreoretinal disorders.
Literature
1.
Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, editor. Pharmacology of the eye. New York: Springer-Verlag, 1984: 19–116CrossRef
2.
Kunou N, Ogura Y, Honda Y, et al. Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate. J Biomed Mater Res 2000 Sep 15; 51(4): 635–41PubMedCrossRef
3.
Sakurai E, Matsuda Y, Ozeki H, et al. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest Ophthalmol Vis Sci 2001; 42(9): 2043–8PubMed
4.
Okabe J, Kimura H, Kunou N, et al. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci 2003; 44(2): 740–4PubMedCrossRef
5.
6.
7.
von Burkersroda F, Schedl L, Gopferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002; 23(21): 4221–31CrossRef
8.
Brunner A, Mader K, Gopferich A. pH and osmotic pressure inside biodegradable microspheres during erosion. Pharm Res 1999; 16(6): 847–53PubMedCrossRef
9.
Lucke A, Kiermaier J, Gopferich A. Peptide acylation by poly(alpha-hydroxy esters). Pharm Res 2002; 19(2): 175–81PubMedCrossRef
10.
Ibrahim MA, Ismail A, Fetouh MI, et al. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J Control Release 2005; 106(3): 241–52PubMedCrossRef
11.
Miller RA, Brady JM, Cutright DE. Degradation rates of oral resorbable implants (polylactates and poly-glycolates): rate modification with changes in PLA/PGA copolymer ratios. J Biomed Mater Res 1977; 11(5): 711–9PubMedCrossRef
12.
Kuno N, Ogura Y, Hashizoe M, et al. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implants in rabbits. J Control Release 1995; 37: 143–50CrossRef
13.
Kuno N, Ogura Y, Yasukawa T, et al. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release 2000; 68(2): 263–71CrossRef
14.
Hora MS, Rana RK, Nunberg JH, et al. Release of human serum albumin from poly(lactide-co-glycolide) microspheres. Pharm Res 1990; 7(11): 1190–4PubMedCrossRef
15.
Sanders LM, Kent JS, McRae GI, et al. Controlled release of a luteinizing hormone-releasing hormone analogue from poly(d,l-lactide-co-glycolide) microspheres. J Pharm Sci 1984; 73(9): 1294–7PubMedCrossRef
16.
Pitt CG, Gratzl MM, Kimmel GL, et al. Aliphatic polyesters: II. The degradation of poly(DL-lactide), poly(µ-ca-prolactone) and their copolymers in vivo. Biomaterials 1981; 2: 215–20PubMedCrossRef
17.
Li SM, Garreau H, Vert M. Structure-property relationships in the case of degradation of massive aliphatic poly (α-hydroxy acids) in aqueous media. Part 1: poly (DL-lactic acid). J Mater Sci Mater Med 1990; 1: 123–30CrossRef
18.
Li SM, Garreau H, Vert M. Structure-property relationships in the case of degradation of massive aliphatic poly (α-hydroxy acids) in aqueous media. Part 2: degradation of lactide-glycolide copolymers, PLA37.5GA25 and PLA75GA25. J Mater Sci Mater Med 1990; 1: 131–9CrossRef
19.
Li SM, Garreau H, Vert M. Structure-property relationships in the case of degradation of massive aliphatic poly (α-hydroxy acids) in aqueous media. Part 3: influence of the morphology of poly (L-lactic acid). J Mater Sci Mater Med 1990; 1: 198–206CrossRef
20.
Giordano GG, Chevez-Barrios P, Refojo MF, et al. Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres. Curr Eye Res 1995; 14(9): 761–8PubMedCrossRef
21.
Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv 2001; 52: 5–16CrossRef
22.
Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28: 5–24PubMedCrossRef
23.
Leong KW, Brott BC, Langer R. Bioerodible poly-anhydrides as drug-carrier matrices. I: characterization, degradation, and release characteristics. J Biomed Mater Res 1985; 19(8): 941–55PubMedCrossRef
24.
Brem H, Kader A, Epstein JI, et al. Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. Sel Cancer Ther 1989; 5(2): 55–65PubMedCrossRef
25.
Brem H, Tamargo RJ, Olivi A, et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994; 80(2): 283–90PubMedCrossRef
26.
Jampel HD, Leong KW, Dunkelburger GR, et al. Glaucoma filtration surgery in monkeys using 5-fluorouridine in polyanhydride disks. Arch Ophthalmol 1990; 108(3): 430–5PubMedCrossRef
27.
Jampel HD, Thibault D, Leong KW, et al. Glaucoma filtration surgery in nonhuman primates using Taxol and etoposide in polyanhydride carriers. Invest Ophthalmol Vis Sci 1993; 34(11): 3076–83PubMed
28.
Lee DA, Flores RA, Anderson PJ, et al. Glaucoma filtration surgery in rabbits using bioerodible polymers and 5-fluorouracil. Ophthalmology 1987; 94(12): 1523–30PubMed
29.
Lee DA, Leong KW, Panek WC, et al. The use of bioerodible polymers and 5-fluorouracil in glaucoma filtration surgery. Invest Ophthalmol Vis Sci 1988; 29(11): 1692–7PubMed
30.
31.
Bausch & Lomb. Vitrasert®: sterile intravitreal implant with Cytovene® (ganiciclovir, 4.5 mg) [online]. Available from URL: http://​www.​bausch.​com [Accessed 2009 Jun 23]
32.
Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 107(11): 2024–33PubMedCrossRef
33.
Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41(11): 3569–75PubMed
34.
Jaffe GJ, McCallum RM, Branchaud B, et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005; 112(7): 1192–8PubMedCrossRef
35.
36.
37.
38.
Kane FE, Burdan J, Cuino A, et al. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008; 5(9): 1039–46PubMedCrossRef
39.
Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002; 43(10): 3292–8PubMed
40.
Bush RA, Lei B, Tao W, et al. Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. Invest Ophthalmol Vis Sci 2004; 45(7): 2420–30PubMedCrossRef
41.
42.
Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006; 103(10): 3896–901PubMedCrossRef
43.
44.
45.
Dugel PU, Fliott D, Cantrill HL, et al. I-Vation™ TA: 24-month clinical results of the phase I safety and preliminary efficacy study [abstract no. 4332]. Association for Research in Vision and Ophthalmology Annual Meeting; 2009 May 3–7; Fort Lauderdale (FL)
46.
Holland GN, Pepose JS, Pettit TH, et al. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983; 90(8): 859–73PubMed
47.
Palestine AG, Rodrigues MM, Macher AM, et al. Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology 1984; 91(9): 1092–9PubMed
48.
49.
Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277(5322): 112–6PubMedCrossRef
50.
Mitchell SM, Membrey WL, Youle MS, et al. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol 1999; 83(6): 652–5PubMedCrossRef
51.
Stephenson J. The art of ‘HAART’: researchers probe the potential and limits of aggressive HIV treatments. JAMA 1997; 277(8): 614–6PubMedCrossRef
52.
Vrabec TR, Baldassano VF, Whitcup SM. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts. Ophthalmology 1998; 105(7): 1259–64PubMedCrossRef
53.
Ogura Y, Ikada Y, inventors. Biodegradable scleral plug. US patent 5707643. 1998
54.
Ryan SJ, Stout JT, Dugel PU. Subretinal neovascularization. In: Ryan SJ, editor. Retina. St Louis (MO): Mosby, 1994: 1027–47
55.
Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992; 99: 933–43PubMed
56.
57.
58.
Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145: 249–56PubMedCrossRef
59.
Arevalo JF, Fromow-Guerra J, Sanchez JG, et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina 2008; 28: 1387–94PubMedCrossRef
60.
Avila MP, Farah ME, Santos A, et al. Twelve-month short-term safety and visual acuity results from a multicentre, prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Br J Ophthalmol 2008; 93: 305–9PubMedCrossRef
61.
62.
Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzo-porphyrin derivative. Br J Cancer 1994; 69(5): 833–9PubMedCrossRef
63.
Amin K, Wasan KM, Albrecht RM, et al. Cell association of liposomes with high fluid anionic phospholipid content is mediated specifically by LDL and its receptor, LDLr. J Pharm Sci 2002; 91(5): 1233–44PubMedCrossRef
64.
Lucentis Utilizing Visudyne (LUV Trial) combination therapy in the treatment of age-related macular degeneration [ClinicalTrials.gov identifier NCT00423189]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Jun 23]
65.
Photodynamic therapy combined with bevacizumab versus bevacizumab alone for neovascular age-related macular degeneration (ARMAST) [ClinicalTrials.gov identifier NCT00696592]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Jun 23]
66.
Safety and efficacy of oral PTK787 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) (ADVANCE) [ClinicalTrials.gov identifier NCT00138632]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Jun 23]
67.
TAC-PF, Avastin® in combination with photodynamic therapy to treat age related macular degeneration (VER-TACL) [ClinicalTrials.gov identifier NCT00464347]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Jun 23]
68.
Reduced fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL) [Clinical Trials.gov identifier NCT00492284]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Jun 23]
69.
Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65(1–2): 271–84PubMedCrossRef
70.
Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989; 6(3): 193–210PubMed
71.
Ideta R, Yanagi Y, Tamaki Y, et al. Effective accumulation of polyion complex micelle to experimental choroidal neovascularization in rats. FEBS Lett 2004; 557(1–3): 21–5PubMedCrossRef
72.
Ideta R, Tasaka F, Yanagi Y, et al. Photodynamic therapy for choroidal neovascularization using polyion complex micelle [abstract no. 33]. 5th International Symposium on Ocular Pharmacology and Therapeutics; 2004 Mar 11–14; Monte Carlo
73.
Yasukawa T, Kimura H, Tabata Y, et al. Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. Invest Ophthalmol Vis Sci 1999; 40(11): 2690–6PubMed
74.
Kamizuru H, Kimura H, Yasukawa T, et al. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci 2001 Oct; 42(11): 2664–72PubMed
75.
Yasukawa T, Kimura H, Tabata Y, et al. Targeting of interferon to choroidal neovascularization by use of dextran and metal coordination. Invest Ophthalmol Vis Sci 2002; 43(3): 842–8PubMed
76.
Beeley NR, Rossi JV, Mello-Filho PA, et al. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J Biomed Mater Res A 2005; 73(4): 437–44PubMed
77.
78.
Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464–74PubMed
79.
Bandello F, Pognuz R, Polito A, et al. Diabetic macular edema: classification, medical and laser therapy. Semin Ophthalmol 2003; 18: 251–8PubMedCrossRef
80.
Early Treatment Diabetic Retinopathy Study Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796–806CrossRef
81.
Jermak CM, Dellacroce JT, Heffez J, et al. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007; 52: 503–22PubMedCrossRef
82.
De Carvalho RPP. Pharmacokinetics of a novel intra-vitreous dexamethasone biodegradable drug delivery system (DEX-BDD) [abstract no. 3874]. Association for Research in Vision and Ophthalmology Annual Meeting; 2002 May 5–10; Fort Lauderdale (FL)
83.
Kuppermann BD, Blumenkranz MS, Haller JA, et al. An intravitreous dexamethasone bioerodible drug delivery system for the treatment of persistent diabetic macular edema [abstract no. 4289]. Association for Research in Vision and Ophthalmology Annual Meeting; 2003 May 4–9; Fort Lauderdale (FL)
84.
Haller JA, Blumenkranz MS, Williams GA, et al. Treatment of persistent macular edema associated with central and branch retinal vein occlusion with extended delivery of intravitreal dexamethasone [abstract no. 4311]. Association for Research in Vision and Ophthalmology Annual Meeting; 2003 May 4–9; Fort Lauderdale (FL)
85.
Williams GA, Blumenkranz MS, Haller JA, et al. Treatment of persistent macular edema (PME) associated with uveitis or Irvine-Gass syndrome (IGS) with an intravitreal bioerodible sustained dexamethasone release implant; a prospective controlled multi-center clinical trial [abstract no. 4309]. Association for Research in Vision and Ophthalmology Annual Meeting; 2003 May 4–9; Fort Lauderdale (FL)
86.
87.
Cardillo JA, Souza-Filho AA, Oliveira AG. Intravitreal bioerudivel sustained-release triamcinolone microspheres system (RETAAC): preliminary report of its potential usefulness for the treatment of diabetic macular edema. Arch Soc Esp Oftalmol 2006; 81: 675–82PubMedCrossRef
88.
89.
Campochiaro P, C99-PKC412-003 Study Group. Phase 2 study results of oral PKC412 in diabetic macular edema [abstract no. 4286]. Association for Research in Vision and Ophthalmology Annual Meeting; 2003 May 4–9; Fort Lauderdale (FL)
90.
Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003; 44(11): 4989–93PubMedCrossRef
91.
92.
93.
Sall JW, Klisovic DD, O’Dorisio MS, et al. Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp Eye Res 2004; 79(4): 465–76PubMedCrossRef
94.
Grant MB, Caballero Jr S. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4(4): 199–203PubMedCrossRef
95.
Hernaez-Ortega MC, Soto-Pedre E, Martin JJ. Sandostatin LAR for cystoid diabetic macular edema: a 1-year experience. Diabetes Res Clin Pract 2004; 64(1): 71–2PubMedCrossRef
96.
Collins W, Kiese B, Fidora H, et al. Efficacy and safety of Sandostatin LAR (octreotide), a somatostatin analog, in diabetic retinopathy: study design of an ongoing phase 3 clinical trial in North America and Brazil [abstract]. American Academy of Ophthalmology Annual Meeting; 2005 Oct 14–18; Chicago (IL)
97.
Solomon SD, Sunness JS, Cooney MJ. Geographic atrophy. In: Lim JI, editor. Age-related macular degeneration. New York: Marcel Dekker, Inc., 2002: 83–99
98.
Trielsch JM, Javitt JC, Coleman A, et al. The prevalence of blindness and visual impairment among nursing home residents in Baltimore. N Engl J Med 1995; 332: 1205–9CrossRef
99.
Seddon JM. Epidemiology of age-related macular degeneration. In: Ryan SJ, editor. Retina. St Louis (MO): Mosby, 2001: 1039–50
100.
Safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy due to age-related macular degeneration (AMD) [ClinicalTrials.gov identifier NCT00658619]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Jun 23]
101.
An exploratory study to evaluate the safety of brimonidine intravitreal implant in patients with retinitis pigmentosa [ClinicalTrials.gov identifier NCT00661479]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Jun 23]
102.
Donoso LA, Kim D, Frost A, et al. The role of inflammation in the pathogenesis of age-related macular degeneration. Survey Ophthalmol 2006; 51: 137–52CrossRef
103.
Magnusson KP, Duan S, Sigurdsson H, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006; 3: e5
104.
Mullins RF, Russell SR, Anderson DH, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 2000; 14: 835–46PubMed
105.
Johnson LV, Ozaki S, Staples MK, et al. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000; 70: 441–9PubMedCrossRef
106.
Anderson DH, Mullins RF, Hageman GS, et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002; 134: 411–31PubMedCrossRef
107.
Johnson LV, Leitner WP, Staples MK, et al. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res 2001; 73: 887–96PubMedCrossRef
108.
Cook GP, Downing J, Rice MA, et al. Injectable PLGA-based formulations for sustained delivery of therapeutic agents for intraocular applications [abstract no. 3490]. Association for Research in Vision and Ophthalmology Annual Meeting; 2009 May 3–7; Fort Lauderdale (FL)
109.
Campochiaro PA. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol 1997; 115: 237–41PubMedCrossRef
110.
111.
Charteris DG. Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment. Br J Ophthalmol 1995; 79(10): 953–60PubMedCrossRef
112.
Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992; 33(11): 3125–30PubMed
113.
Rahimy MH, Peyman GA, Fernandes ML, et al. Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations. J Ocul Pharmacol 1994; 10(3): 561–70PubMedCrossRef
114.
Salah-Eldin M, Peyman GA, el-Aswad M, et al. Evaluation of toxicity and efficacy of a combination of antineoplastic agents in the prevention of PVR. Int Ophthalmol 1994; 18(2): 53–60PubMedCrossRef
115.
Einmahl S, Behar-Cohen F, D’Hermies F, et al. A new poly(ortho ester)-based drug delivery system as an adjunct treatment in filtering surgery. Invest Ophthalmol Vis Sci 2001; 42(3): 695–700PubMed
116.
Blumenkranz M, Hernandez E, Ophir A, et al. 5-Fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 1984; 91(2): 122–30PubMed
117.
Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001; 108(7): 1179–83PubMedCrossRef
118.
Charteris DG, Aylward GW, Wong D, et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 2004; 111(12): 2240–5PubMedCrossRef
119.
Yang CS, Khawly JA, Hainsworth DP, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 1998; 116(1): 69–77PubMed
120.
Berger AS, Cheng CK, Pearson PA, et al. Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1996; 37(11): 2318–25PubMed
121.
Cardillo JA, Farah ME, Mitre J, et al. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 2004; 88(9): 1201–5PubMedCrossRef
122.
Weleber RG, Gregory-Evans K. Retinitis pigmentosa and allied disorders. In: Ryan SJ, editor. Retina. St Louis (MO): Mosby, 2006: 395–498
123.
Faktorovich EG, Steinberg RH, Yasumura D, et al. Basic fibroblast growth factor and local injury protect photo-receptors from light damage in the rat. J Neurosci 1992; 12(9): 3554–67PubMed
124.
LaVail MM, Unoki K, Yasumura D, et al. Multiple growth factors, cytokines, and neurotrophins rescue photo-receptors from the damaging effects of constant light. Proc Natl Acad Sci U S A 1992; 89(23): 11249–53PubMedCrossRef
125.
Machida S, Tanaka M, Ishii T, et al. Neuroprotective effect of hepatocyte growth factor against photoreceptor degeneration in rats. Invest Ophthalmol Vis Sci 2004; 45(11): 4174–82PubMedCrossRef
126.
Ogata N, Wang L, Jo N, et al. Pigment epithelium derived factor as a neuroprotective agent against ischemic retinal injury. Curr Eye Res 2001; 22(4): 245–52PubMedCrossRef
127.
Takita H, Yoneya S, Gehlbach PL, et al. Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44(10): 4497–504PubMedCrossRef
128.
Cayouette M, Smith SB, Becerra SP, et al. Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degeneration. Neurobiol Dis 1999; 6(6): 523–32PubMedCrossRef
129.
Cao W, Tombran-Tink J, Elias R, et al. In vivo protection of photoreceptors from light damage by pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2001; 42(7): 1646–52PubMed
130.
Sakai T, Kuno N, Takamatsu F, et al. Prolonged protective effect of basic fibroblast growth factor-impregnated nanoparticles in Royal College of Surgeons rats. Invest Ophthalmol Vis Sci 2007; 48: 3381–7PubMedCrossRef
Metadata
Title
Biodegradable Intraocular Therapies for Retinal Disorders
Progress to Date
Authors
Noriyuki Kuno, PhD
Shinobu Fujii
Publication date
01-02-2010
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 2/2010
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/11530970-000000000-00000

Other articles of this Issue 2/2010

Drugs & Aging 2/2010 Go to the issue

Adis Spotlight

Spotlight on Memantine in Moderate to Severe Alzheimer’s Diseasey

Review Article

Anticytokine Therapy for Osteoarthritis

Current Opinion

ACE Inhibitor and Angiotensin II Type 1 Receptor Antagonist Therapies in Elderly Patients with Diabetes Mellitus

Original Research Article

Drug Burden Index and Potentially Inappropriate Medications in Community-Dwelling Older People

Original Research Article

Disparities in Combination Drug Therapy Use in Older Adults with Coronary Heart Disease

Adis Drug Evaluation

Zoster Vaccine (Zostavax®)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits